Isofol Medical AB
5IU
Company Profile
Business description
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Contact
Arvid Wallgrens Backe 20
Biotech Center
GothenburgSE-413 46
SWET: +46 31137331
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,887.60 | 17.10 | 0.19% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,686.91 | 825.10 | 1.69% |
| FTSE 100 | 10,378.82 | 165.71 | 1.62% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,889.77 | 216.53 | 0.88% |
| Nikkei 225 | 59,284.92 | 632.54 | -1.06% |
| NZX 50 Index | 12,903.31 | 133.01 | 1.04% |
| S&P 500 | 7,207.97 | 72.02 | 1.01% |
| S&P/ASX 200 | 8,665.80 | 25.60 | 0.30% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |